Gemer Sita 50mg/2mg/1000mg Tablet IR is a combination oral antidiabetic medication containing Sitagliptin 50mg, Glimepiride 2mg, and Metformin 1000mg. This formulation is indicated for the management of type 2 diabetes mellitus in patients inadequately controlled on monotherapy or dual therapy. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances incretin hormone levels, thereby increasing insulin release and decreasing glucagon levels in a glucose-dependent manner. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta-cell insulin secretion, contributing to improved glycemic control. Metformin, a biguanide, primarily reduces hepatic glucose production and improves peripheral insulin sensitivity. The immediate-release (IR) tablet allows for rapid onset of action, facilitating effective glycemic regulation. Gemer Sita is typically prescribed as part of a comprehensive diabetes management plan including diet and exercise. It is essential to monitor blood glucose levels regularly to minimize the risk of hypoglycemia, particularly due to the sulfonylurea component. Caution is advised in patients with renal or hepatic impairment, and contraindications include severe renal dysfunction and metabolic acidosis. Adverse effects may include gastrointestinal disturbances, hypoglycemia, and rare lactic acidosis. Dose adjustments should be individualized based on patient response and tolerability.